Technical Analysis for ABIO - ARCA biopharma, Inc.

Grade Last Price % Change Price Change
grade F 0.521 -8.60% -0.05
ABIO closed down 8.6 percent on Tuesday, April 24, 2018, on 17 percent of normal volume.
3 Watchers
Intraday Alerts Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ABIO trend table...

Date Alert Name Type % Chg
Apr 24 Oversold Stochastic Weakness 0.00%
Apr 23 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -8.60%
Apr 23 Spinning Top Other -8.60%
Apr 23 Upper Bollinger Band Touch Strength -8.60%
Apr 20 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -6.96%
Apr 20 Inside Day Range Contraction -6.96%
Apr 20 Upper Bollinger Band Touch Strength -6.96%
Apr 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -8.60%
Apr 19 Inside Day Range Contraction -8.60%
Apr 19 Upper Bollinger Band Touch Strength -8.60%

Older signals for ABIO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:
Profile
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. ARCA biopharma, Inc. is headquartered in Broomfield, Colorado.
Is ABIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Apr 23 ARCA Biopharma and Medtronic extend Gencaro clinical trial collaboration agreement
Apr 23 ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement
Apr 3 Blog Exposure - Insmed Announced Submission of New Drug to FDA for Patients with Nontuberculous Mycobacterial Lung Disease
Mar 22 ARCA biopharma reports FY results
Mar 22 ARCA biopharma Announces Fiscal Year 2017 Financial Results and Provides Corporate Update
Mar 1 ARCA Biopharma Has One More Shot To Get It Right
Feb 27 Here’s Why Arca Biopharma Inc (ABIO) Shares Are Skyrocketing Today
Feb 27 ARCA biopharma (ABIO) Top-Line Data From Genetic-AF Phase 2B Clinical Trial - Slideshow'
Feb 26 ARCA biopharma And ObsEva Just Put Out Clinical Trial Data
Feb 26 Midday Gainers / Losers (2/26/2018)
See more ABIO news...
Indicators
Indicator Value
52 Week High 2.76
52 Week Low 0.45
Average Volume 1,286,069
200-Day Moving Average 1.316
50-Day Moving Average 0.7678
20-Day Moving Average 0.5291
10-Day Moving Average 0.5538
Average True Range 0.0663
ADX 20.7
+DI 21.51
-DI 19.35
Chandelier Exit (Long, 3 ATRs ) 0.4511
Chandelier Exit (Short, 3 ATRs ) 0.6589
Upper Bollinger Band 0.5936
Lower Bollinger Band 0.4646
Percent B (%b) 0.44
BandWidth 24.381024
MACD Line -0.0495
MACD Signal Line -0.0733
MACD Histogram 0.0238
Fundamentals Value
Market Cap 6.12 Million
Num Shares 11.7 Million
EPS -2.05
Price-to-Earnings (P/E) Ratio -0.25
Price-to-Sales 0.00
Price-to-Book 0.92
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.60
Resistance 3 (R3) 0.60 0.59 0.58
Resistance 2 (R2) 0.59 0.57 0.58 0.58
Resistance 1 (R1) 0.55 0.56 0.55 0.55 0.58
Pivot Point 0.54 0.54 0.53 0.53 0.54
Support 1 (S1) 0.50 0.52 0.50 0.50 0.47
Support 2 (S2) 0.49 0.51 0.48 0.46
Support 3 (S3) 0.45 0.49 0.46
Support 4 (S4) 0.45